Zydus Lifesciences Limited CC-Sep24.pdf · 2024-11-12
Yeah. Hi, sir. Hope I am audible.
Yes, sir. Sir, on the Sitagliptin 505(b)(2) opportunity which you spoke about for next year . Sir, next year the Sitagliptin generic market also opens up in mid-2025 and there are already, let's say, around 8 to 10 generic companies who have tentative approval on the product. So, with the generic market opening up on 16 of 22 Sitagliptin next year , so, what kind of a traction do you think you would be able to garner for your 505(b)(2) product?